Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Abeona Therapeutics (NQ: ABEO )

2.110 USD -0.010 (-0.47%)
Streaming Delayed Price Updated: 9:51 AM EST, Jan 25, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Abeona Therapeutics

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Abeona Therapeutics Announces Successful Type B Meeting with FDA for Pivotal Phase 3 VIITAL™ Study of EB-101 in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Clinical trial amendment successfully completed for co-primary endpoints of partial wound closure and mean pain reduction 
From GlobeNewswire News Releases
Abeona Therapeutics Announces Acceptance of Late-Breaker Abstracts Highlighting New Clinical Data for Novel AAV-based Gene Therapies in MPS IIIA and MPS IIIB at WORLDSymposium™
From GlobeNewswire News Releases
Abeona Therapeutics Reports Third Quarter Financial Results
Conference call scheduled for Tuesday, November 10, 2020 at 8:30 a.m. ET 
From GlobeNewswire News Releases
Abeona Therapeutics Announces the Appointment of Michael Amoroso as Chief Operating Officer
From GlobeNewswire News Releases
Abeona Therapeutics’ Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan
From GlobeNewswire News Releases
Abeona Therapeutics Announces Leadership and Board Transitions
From GlobeNewswire News Releases
Abeona Therapeutics to Participate in Upcoming Investor Conferences
From GlobeNewswire News Releases
Abeona Therapeutics and Taysha Gene Therapies Enter into Licensing and Inventory Purchase Agreements for ABO-202, a Clinical Stage, Novel, One-time Gene Therapy for CLN1 Disease
From GlobeNewswire News Releases
Abeona Therapeutics Reports Second Quarter Financial Results and Business Updates
From GlobeNewswire News Releases
Abeona Therapeutics Announces Two Presentations Related to Its RDEB Clinical Program at the Society for Pediatric Dermatology 45th Annual Meeting
From GlobeNewswire News Releases
Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Commercial Officer
To lead Abeona’s commercial organization, EB-101 commercialization planning and pre-commercial strategy for AAV-based gene therapy programs 
From GlobeNewswire News Releases
Abeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL™ Study in RDEB after COVID-19 Related Pause and Announces Progress in Patient Enrollment in MPS III Studies
From GlobeNewswire News Releases
Abeona Therapeutics Announces Upcoming Data Presentations at the Society for Pediatric Dermatology 45th Annual Meeting
From GlobeNewswire News Releases
Abeona Therapeutics Further Strengthens Board with Appointment of Two New Independent Directors
From GlobeNewswire News Releases
Abeona Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference
From GlobeNewswire News Releases
Abeona Therapeutics Reports First Quarter Financial Results and Business Updates
From GlobeNewswire News Releases
Abeona Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Abeona Therapeutics Appoints Brian Pereira and Shawn Tomasello to the Board of Directors
Company appoints experienced industry leaders Brian Pereira as Executive Chairman and Shawn Tomasello as Independent Board Member 
From GlobeNewswire News Releases
INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Abeona Therapeutics Inc. for Potential Breach of Fiduciary Duty Claims
From GlobeNewswire News Releases
Abeona Therapeutics Stakeholder Letter in Response to the COVID-19 Pandemic
From GlobeNewswire News Releases
NASDAQ: ABEO Long Term Shareholder Notice: Investigation over Possible Wrongdoing at Abeona Therapeutics Inc.
San Diego, CA -- (SBWIRE) -- 03/23/2020 -- An investigation on behalf of current long term investors in Abeona Therapeutics Inc. (NASDAQ: ABEO) shares over possible breaches of fiduciary duty by... 
From SBWire - Latest Press Releases
Abeona Therapeutics Announces First Patient Treated in Pivotal Phase III Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
From GlobeNewswire News Releases
Abeona Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Updates
From GlobeNewswire News Releases
Abeona Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference
From GlobeNewswire News Releases
Abeona Therapeutics Announces Positive Interim Data from MPS III Gene Therapy Programs Presented at WORLDSymposium™
From GlobeNewswire News Releases
Abeona Therapeutics Announces Participation in Inaugural World Congress on Epidermolysis Bullosa
From GlobeNewswire News Releases
Abeona Therapeutics Announces Issuance of U.S. Patent for AIM™ Capsids
From GlobeNewswire News Releases
Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
From GlobeNewswire News Releases
THURSDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Abeona Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
THURSDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Abeona Therapeutics Inc. 
From Business Wire News Releases
ABEONA EQUITY LOSS ALERT: ROSEN, A LEADING LAW FIRM, Reminds Abeona Therapeutics Inc. Investors of Important Thursday Deadline in Securities Class Action - ABEO
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.